Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Reed Elsevier on track!

3 Posts
| Omlaag ↓
  1. [verwijderd] 13 november 2008 09:53
    November 13, 2008
    Reed Elsevier today reaffirmed that it is on track to deliver on its goals this year of good revenue growth, meaningful margin improvement and strong growth in adjusted earnings per share.
    The £2.1bn/€2.7bn acquisition of ChoicePoint Inc was completed on 19 September 2008. The process of integration of ChoicePoint with the LexisNexis Risk Group is now underway under a new leadership team formed from senior management of both businesses. The business is performing in line with expectations and the integration plans are on track to deliver the expected cost synergy benefits.

    The process of divestment of Reed Business Information is at an advanced stage although in the present economic and credit environment a satisfactory outcome cannot be certain. As part of the process, a consortium of financing banks are in discussions with a small number of prospective buyers to provide financing. Reed Elsevier has indicated a willingness to provide financing support for any successful bid.

    The major restructuring programme announced in February 2008 is progressing well and is expected to deliver the targeted £15m/€19m cost savings in 2008, building to £100m/€125m of annual savings by 2011.

    Sir Crispin Davis, Chief Executive Officer, said: “The business is on track for a very successful year and we expect to deliver Reed Elsevier’s strongest constant currency earnings growth in over a decade. Whilst the economic environment is undoubtedly challenging, our businesses are more resilient than most and we are in a strong financial position. We are continuing to invest in expanding our online product offerings to deliver enhanced customer productivity and effectiveness, and together with the restructuring programme we are tightly managing costs. The acquisition of ChoicePoint transforms our position in the risk information and analytics sector and the strategic and financial benefits are very attractive. We are confident that it will deliver the returns expected.”

    The performance trends in Reed Elsevier’s businesses in the second half of the year are as follows:

    Elsevier: Subscription renewals remain very strong and there is good demand in expanding online services. The second half medical publishing programme is going well, particularly in the nursing and health professional sectors, and strong growth is seen in clinical decision solutions. Pharma advertising markets remain weak, but represent a relatively small proportion of Elsevier revenues.

    LexisNexis: The business has seen continued good growth in online information solutions, particularly in the US large law firm market and internationally, although the rate of underlying growth in legal markets is behind last year’s reflecting the tougher economic environment. Corporate and government markets other than risk remain subdued. The risk information and analytics group is performing well, and the insurance business of ChoicePoint continues to grow strongly.

    Reed Exhibitions: The exhibitions business has continued to perform well, with a number of successful shows held in the second half, although the environment is getting tougher. The net cycling in of biennial shows has an additional significant positive effect on 2008 performance and the exhibitions business is expected to deliver very strong results this year.

    Reed Business Information: The performance of the magazine and information business has held up well during the year despite generally difficult economic conditions with strong growth in online information services more than compensating for declines in print. RBI is however now seeing more challenging advertising markets following the recent deterioration in economic outlook.

    The second half has seen a strengthening of the US dollar against both sterling and the euro. For the year as a whole, should current exchange rates prevail, the average sterling exchange rate will have weakened year on year against both the US dollar and the euro whereas the average exchange rate for the euro will have strengthened against the US dollar and sterling. This will result in a positive translation benefit to adjusted earnings per share growth expressed in sterling and an adverse effect on adjusted earnings per share growth expressed in euros.

    The acquisition of ChoicePoint was funded from a facility in two approximately equal tranches, one extendable at Reed Elsevier’s option to March 2010 and the other maturing in March 2011. The facility is expected to be repaid from Reed Elsevier’s strong free cash flow, term debt issuance, the proceeds of a sale of Reed Business Information and other resources.

    - ENDS -

    Enquiries

    Patrick Kerr (Media)
    +44 20 7166 5646

    Sybella Stanley (Investors)
    +44 20 7166 5630
  2. [verwijderd] 13 november 2008 19:57
    wat een topprestatie om in deze markt dergelijke prestaties maar vooral ook verwachtingen uit te spreken....het beste jaar in de afgelopen 10 jaar....dat biedt kansen voor verdere stijgingen van het aandeel in de komende dagen en zeer onzekere tijden voor andere bedrijven...ons Elsje als veilige haven.....
  3. [verwijderd] 13 november 2008 20:29
    uit de telegraaf.nl....dit is een berichtje van vanochtend..uiteindelijk werd de koerstijging nog mooier en groeide uit naar bijna 9 procent.....
    greetz

    Het uitgeefconcern Reed Elsevier maakte donderdag een opvallende koerssprong op de beurs in Amsterdam. Beleggers toonden zich tevreden over de trading update die het bedrijf voorbeurs gaf. De koers steeg meer dan 6 procent.
    Volgens Theodoor Gilissen werd in de trading update de goede gang van zaken bij Reed Elsevier bevestigd. De zakenbank gaat er nog steeds vanuit dat de omzet bij de de uitgever van professionele informatie dit jaar op eigen kracht met 5 procent zal toenemen. De winstgroei per aandeel moet met meer dan 12 procent kunnen toenemen.
    Reed Elsevier hield het bij zijn trading update op een “goede omzetgroei” en een duidelijke verbetering van de winstgevendheid. Dit is hetzelfde geluid als bij de presentatie van de halfjaarcijfers eind juli. De koers van Reed Elsevier steeg toen ook sterk.
    Bezorgdheid
    Het bedrijf toonde donderdag wel bezorgdheid over de verkoop van zijn tijdschriftentak Reed Business Information. Dit zal van invloed zijn op de prijs die het zal ontvangen, aldus zakenbank Petercam.
    Het aandeel Reed Elsevier noteerde rond 10.30 uur een koers van 9,43 euro. Dit betekende een stijging van ruim 6 procent. Het aandeel is dit jaar met ruim een derde in waarde gedaald. Petercam hanteert een reduce-advies, Theodoor Gilissen vindt het aandeel koopwaardig (buy).
    Mail
3 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.106
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.078
ABO-Group 1 23
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.829
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.804
Aedifica 3 925
Aegon 3.258 323.042
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.349
Air France - KLM 1.025 35.265
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.180
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.748
AMG 971 134.231
AMS 3 73
Amsterdam Commodities 305 6.744
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 495
Antonov 22.632 153.605
Aperam 92 15.047
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.943
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.597
ASML 1.766 109.805
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.834
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.447

Macro & Bedrijfsagenda

  1. 24 maart

    1. Samengestelde inkoopmanagersindex maart (Jap)
    2. Samengestelde inkoopmanagersindex maart (Fra)
    3. Samengestelde inkoopmanagersindex maart (Dld)
    4. Samengestelde inkoopmanagersindex maart (eur)
    5. Samengestelde inkoopmanagersindex maart (VK)
    6. Chicago Fed index februari (VS)
    7. Samengestelde inkoopmanagersindex maart (VS)
  2. 25 maart

    1. Ifo ondernemersvertrouwen maart (Dld)
    2. Case Shiller huizenprijzen januari (VS)
    3. Shell beleggersdag
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht